7Baggers
Quarterly
Annual
    Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 
      
    		                                          
      assets
    		                                          
      current assets:
    		                                          
      cash and cash equivalents
    		206,535,000 273,721,000 35,482,000 59,150,000 20,291,000 30,691,000 52,753,000 73,995,000 125,806,000 68,963 32,897,000 43,326,000 28,193 47,273,000 96,051,000 56,794,000 24,869 43,462,000 28,081,000 125,574,000 48,995,000 41,795,000 44,726,000 65,581,000 23,054,000 23,009,000 9,509,000 13,673,000 10,495,000 6,821,000 12,411,000 21,197,000 7,706,000 6,691,000 11,702,000 10,841,000 11,586,000 16,356,000 8,002,000 22,342,000 24,401,000 32,080,000 
      marketable securities
    		187,720,000 165,057,000 178,362,000 177,215,000 115,194,000 122,724,000 111,130,000 114,564,000 60,729,000 44,825 73,237,000 82,132,000 118,130 113,991,000 72,856,000 119,438,000 166,076 175,132,000 213,126,000 139,182,000 129,669,000 156,350,000 167,353,000 163,955,000 74,156,000 79,160,000 7,217,000 9,723,000 6,499,000 16,313,000 16,705,000 14,057,000 33,774,000 40,162,000 15,329,000 21,950,000 23,209,000 26,270,000 15,624,000 6,191,000 6,843,000  
      prepaid expenses and other current assets
    		9,547,000 8,881,000 10,227,000 6,355,000 2,588,000                                      
      total current assets
    		403,802,000 447,659,000 224,071,000 242,720,000 138,073,000 155,124,000 166,611,000 192,046,000 191,099,000 119,576 113,813,000 133,273,000 151,585 166,129,000 174,102,000 185,949,000 202,923 227,771,000 249,813,000 270,064,000 181,562,000 202,255,000 216,715,000 231,176,000 103,544,000 103,659,000 17,869,000 24,557,000 18,528,000 24,480,000 30,164,000 36,490,000 42,794,000 48,573,000 28,303,000 34,492,000 37,229,000 44,399,000 25,432,000 30,933,000 32,239,000 32,113,000 
      non-current marketable securities
    		21,932,000      6,874,000 4,885,000 8,067,000                                  
      property and equipment
    		465,000 453,000 626,000 729,000 701,000 845,000 993,000 1,024,000 1,178,000 1,341 1,511,000 1,690,000 1,761 1,929,000 2,075,000 2,242,000 2,409 2,549,000 2,693,000 2,794,000 2,905,000 90,000 90,000 103,000 69,000 51,000 59,000 68,000 77,000 85,000 90,000 59,000 64,000 69,000 75,000 80,000 86,000 91,000 87,000 60,000 3,000 9,000 
      right-of-use assets
    		5,260,000                                          
      other assets
    		3,227,000 2,879,000 1,854,000 1,733,000 2,909,000 3,081,000 3,026,000 2,448,000 1,720,000 1,721 1,447,000 1,446,000 207 160,000 160,000 160,000 160 1,261,000 730,000 1,122,000 2,280,000 1,363,000 1,363,000 980,000 634,000 634,000 804,000 754,000 754,000 221,000 221,000 221,000 221,000 221,000 292,000 158,000 159,000 159,000 514,000 203,000 258,000 42,000 
      total assets
    		434,686,000 451,048,000 226,650,000 245,319,000 141,852,000 159,247,000 177,724,000 200,642,000 202,318,000 122,902 117,041,000 136,682,000 153,825 168,486,000 176,597,000 188,600,000 205,727 231,800,000 253,435,000 274,157,000 186,747,000 203,708,000 218,168,000 232,259,000 104,247,000 104,344,000 18,732,000 25,379,000 19,359,000 24,786,000 30,475,000 36,770,000 43,079,000 48,863,000 28,670,000 34,730,000 37,474,000 44,649,000 26,033,000 31,196,000 32,500,000 32,164,000 
      liabilities and stockholders’ equity
    		                                          
      current liabilities:
    		                                          
      accounts payable
    		3,828,000 2,731,000 4,589,000 1,633,000 1,096,000 479,000 866,000 199,000 2,728,000 764 1,050,000 1,606,000 231 947,000 476,000 1,213,000 2,503 1,494,000 2,882,000 2,410,000 1,973,000 1,629,000 1,336,000 2,038,000 1,311,000 1,235,000 1,101,000 1,096,000 899,000 935,000 1,272,000 1,777,000 1,008,000 707,000 1,721,000 1,527,000 2,085,000 1,047,000 1,262,000 1,069,000 697,000 1,039,000 
      accrued research and development expenses
    		5,633,000 5,835,000 4,838,000 5,565,000 6,530,000 6,622,000 7,028,000 9,659,000 9,752,000 6,451 4,126,000 3,294,000 4,698 5,729,000 5,437,000 7,351,000 9,218 10,819,000                         
      development financing liability - current portion
    		10,000,000                                          
      deferred collaboration revenue - current portion
    		1,689,000                                          
      other accrued liabilities
    		15,693,000 9,468,000 6,835,000 5,569,000 7,815,000 5,610,000 4,666,000 4,181,000 5,886,000 4,526 3,783,000 3,009,000 4,910 3,693,000 2,686,000 1,641,000 2,722 5,045,000 3,266,000 2,782,000 3,854,000 2,437,000 2,071,000                    
      total current liabilities
    		36,843,000 19,666,000 17,894,000 46,500,000 15,441,000 12,711,000 12,560,000 14,039,000 18,366,000 11,741 8,959,000 7,909,000 9,857 10,462,000 9,478,000 11,922,000 17,636 17,358,000 15,422,000 14,473,000 14,415,000 13,640,000 16,916,000 17,918,000 16,310,000 14,028,000 11,988,000 10,780,000 9,311,000 7,751,000 7,542,000 6,747,000 6,146,000 6,153,000 8,545,000 13,664,000 20,459,000 15,032,000 13,757,000 15,521,000 9,488,000 2,243,000 
      development financing liability - non-current portion
    		99,172,000                                          
      deferred collaboration revenue - non-current portion
    		1,100,000                                          
      lease liabilities - non-current portion
    		5,315,000                                          
      total liabilities
    		142,430,000 124,857,000 118,242,000 141,130,000 105,698,000 99,069,000 95,267,000 93,261,000 69,381,000 35,844 9,947,000 9,036,000 11,119 11,851,000 10,989,000 13,552,000 19,379 19,209,000 17,376,000 16,526,000 16,329,000 15,577,000 18,955,000 20,060,000 19,300,000 17,840,000 16,593,000 16,152,000 15,422,000 14,574,000 15,054,000 14,924,000 14,964,000 15,369,000 10,990,000 16,462,000 23,624,000 18,518,000 17,556,000 19,820,000 13,904,000 12,058,000 
      commitments and contingencies
    		                                          
      stockholders’ equity:
    		                                          
      preferred stock, 0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
    		                                          
      common stock
    		11,000 18,000 17,000 17,000 8,000 8,000 8,000 8,000 8,000 7 7,000 7,000 7 7,000 7,000 7,000 7 7,000 7,000 7,000 6,000 6,000 6,000 6,000 4,000 4,000 3,000 3,000 2,000 2,000 2,000 2,000 2,000 2,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
      additional paid-in capital
    		1,270,328,000 1,262,560,000 1,010,958,000 1,005,877,000 909,329,000 906,968,000 904,609,000 902,217,000 899,798,000 827,365 824,717,000 822,054,000 819,549 817,653,000 815,101,000 814,131,000 812,133 808,866,000 806,001,000 803,718,000 693,534,000 691,771,000 684,326,000 679,846,000 535,503,000 531,986,000 439,376,000 437,536,000 426,895,000 426,219,000 425,552,000 424,981,000 424,422,000 423,809,000 402,136,000 401,361,000 394,622,000 394,182,000 370,552,000 370,276,000 367,435,000 365,033,000 
      accumulated other comprehensive income
    		144,000        -13,000 -1 1,000 -6,000 8 82,000 186,000 -130,000 80 177,000 228,000 45,000                 -14,000 -15,000  3,000 2,000  
      accumulated deficit
    		-978,227,000 -936,325,000 -902,443,000 -901,635,000 -872,857,000 -846,224,000 -821,719,000 -794,625,000 -766,856,000 -740,313 -717,631,000 -694,409,000 -676,858 -661,107,000 -649,686,000 -638,960,000 -625,872 -596,459,000 -570,177,000 -546,139,000 -523,064,000 -503,615,000 -485,052,000 -467,521,000 -450,516,000 -445,473,000 -437,239,000 -428,310,000 -422,959,000 -416,007,000 -410,128,000 -403,136,000 -396,288,000 -390,309,000 -384,444,000 -383,087,000 -380,759,000 -368,037,000 -362,076,000 -358,904,000 -348,842,000 -344,928,000 
      total stockholders’ equity
    		292,256,000 326,191,000 108,408,000 104,189,000 36,154,000 60,178,000 82,457,000 107,381,000 132,937,000 87,058 107,094,000 127,646,000 142,706 156,635,000 165,608,000 175,048,000 186,348 212,591,000 236,059,000 257,631,000 170,418,000 188,131,000 199,213,000 212,199,000 84,947,000 86,504,000 2,139,000 9,227,000 3,937,000 10,212,000 15,421,000 21,846,000 28,115,000 33,494,000 17,680,000 18,268,000 13,850,000 26,131,000 8,477,000 11,376,000 18,596,000 20,106,000 
      total liabilities and stockholders’ equity
    		434,686,000 451,048,000 226,650,000 245,319,000 141,852,000 159,247,000 177,724,000 200,642,000 202,318,000 122,902 117,041,000 136,682,000 153,825 168,486,000 176,597,000 188,600,000 205,727 231,800,000 253,435,000 274,157,000 186,747,000 203,708,000 218,168,000 232,259,000 104,247,000 104,344,000 18,732,000 25,379,000 19,359,000 24,786,000 30,475,000 36,770,000 43,079,000 48,863,000 28,670,000 34,730,000 37,474,000 44,649,000 26,033,000 31,196,000   
      operating lease right-of-use asset
    		 57,000 99,000 137,000 169,000 197,000 220,000 239,000 254,000 264 270,000 273,000 272 268,000 260,000 249,000  219,000 199,000 177,000                       
      deferred collaboration revenue—current portion
    		 1,632,000 1,632,000                                        
      development financing liability
    		 104,091,000 99,248,000 94,630,000 90,227,000 86,152,000 82,333,000 78,685,000 50,320,000 23,259                                 
      deferred collaboration revenue—non-current portion
    		 1,100,000 1,100,000                                        
      long-term portion of operating lease liability
    		    30,000 206,000 374,000 537,000 695,000 844 988,000 1,127,000 1,262 1,389,000 1,511,000 1,630,000 1,743 1,851,000 1,954,000 2,053,000                       
      accumulated other comprehensive loss
    		 -62,000 -124,000 -70,000 -326,000 -574,000 -441,000 -219,000             -58,000 -31,000 -67,000 -132,000 -44,000 -13,000 -1,000 -2,000 -1,000 -2,000 -5,000 -1,000 -21,000 -8,000 -13,000 -7,000       
      deferred collaboration revenue
    		   33,733,000                                       
      prepaid research and development expenses
    		     668,000 1,103,000 1,384,000 2,371,000 5,071 6,060,000 5,631,000 2,221 3,761,000 4,012,000 7,922,000 9,910 7,900,000                         
      other prepaid expenses and current assets
    		     1,041,000 1,625,000 2,103,000 2,193,000 648 1,392,000 1,919,000 2,764 820,000 974,000                            
      accrued interest receivable
    		         69 227,000 265,000 277 284,000 209,000 377,000 687 509,000 725,000 481,000  217,000 405,000       22,000 19,000 96,000 186,000 209,000 83,000 199,000 136,000 223,000 134,000 90,000 68,000  
      accrued restructuring
    		            18 93,000 879,000 1,717,000 3,193                          
      other prepaid expenses
    		               1,418,000 1,381 768,000                         
      operating lease right-of-use assets
    		                235                          
      other liabilities
    		                            13,000 14,000    18,000 16,000      9,000  
      prepaid expenses
    		                  7,881,000 4,827,000 2,594,000 1,793,000 2,131,000 1,367,000 1,208,000 1,368,000 1,126,000 1,128,000 1,369,000 1,324,000 1,029,000 1,140,000 1,128,000 1,491,000 996,000 1,363,000 1,991,000 1,402,000 1,475,000 1,876,000 364,000 33,000 
      accrued clinical trial expenses
    		                  9,274,000 9,281,000  9,574,000 7,877,000                    
      receivable from collaboration
    		                        5,000,000                  
      other current assets
    		                    304,000 2,100,000 2,100,000 273,000 126,000 122,000 17,000 33,000 165,000     20,000 176,000 139,000 96,000 134,000 187,000 266,000 453,000  
      accrued clinical expenses
    		                    8,588,000                      
      warrant liability
    		                      5,632,000 7,648,000 6,091,000 5,862,000 4,343,000 3,279,000 1,145,000 1,177,000 1,259,000 900,000 1,220,000 1,356,000 2,181,000 7,704,000 13,596,000 8,766,000 8,888,000 11,638,000 6,466,000  
      facility loan
    		                       3,219,000 3,108,000 3,001,000 2,897,000 2,797,000 2,700,000 2,607,000 2,041,000 1,262,000 509,000  1,450,000 1,403,000 1,355,000 1,193,000 795,000 410,000 38,000  
      accrued interest payable
    		                       37,000 43,000 49,000 55,000 60,000 66,000 72,000 73,000 73,000 73,000 73,000 29,000 32,000 35,000 36,000 36,000 36,000 36,000  
      deferred rent, less current portion
    		                    1,914,000                      
      facility loan, less current portion
    		                       2,142,000 2,990,000 3,809,000 4,599,000 5,362,000 6,098,000 6,809,000 7,496,000 8,159,000 8,799,000 9,198,000 2,429,000 2,784,000 3,152,000 3,476,000 3,793,000 4,099,000 4,407,000  
      deferred rent, net of current portion
    		                     1,937,000 2,039,000                    
      accrued liabilities
    		                       4,976,000 5,757,000 3,881,000 3,592,000 3,548,000 4,501,000 2,960,000 2,897,000 2,735,000 3,336,000 4,017,000 3,164,000 2,998,000 3,388,000 3,990,000 2,776,000 2,368,000 2,251,000 1,204,000 
      other liabilites
    		                         3,000 6,000 10,000   16,000 18,000 19,000   14,000 13,000 10,000 6,000 200,000   
      contract receivables
    		                                  17,000  211,000 14,000 10,000 168,000 110,000  
      liabilities and redeemable convertible preferred stock and stockholders’ equity
    		                                          
      convertible notes
    		                                          
      redeemable convertible preferred stock
    		                                          
      stockholders’ equity
    		                                          
      preferred stock, 0.0001 par value: 10,000,000 shares authorized at december 31, 2013; no shares authorized at december 31, 2012; no shares issued and outstanding
    		                                          
      total liabilities and redeemable convertible preferred stock and stockholders’ equity
    		                                        32,500,000 32,164,000 
      long term warrant liability
    		                                         5,310,000 
      deferred rent
    		                                         131,000 
      stockholders’ deficit:
    		                                          
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.